Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose range exploration of Sativex for cancer-related pain despite optimized opioid therapy
2007-005225-30Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain comparing Sativex with Placebo (2 arms). Primary endpoint: 30% pain response rate at week 5. Started Dec 2007; status: completed.
02
Drugs
cannabidiol
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2007-005225-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005225-30.